Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?
10:06am, Friday, 27'th Mar 2026
Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity loss.
Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits?
10:02am, Friday, 27'th Mar 2026
MRK stock has surged over 50% in six months, but looming patent risks and weak vaccine sales raise questions on whether investors should hold or trim.
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
12:10pm, Thursday, 26'th Mar 2026
MRK's $6.7B Terns buyout is set to add a promising leukemia drug candidate, boosting its oncology pipeline as it prepares for Keytruda's patent cliff.
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
10:00am, Thursday, 26'th Mar 2026
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
First Bank & Trust Invests $632,000 in Merck & Co., Inc. $MRK
05:15am, Thursday, 26'th Mar 2026
First Bank and Trust bought a new position in Merck and Co., Inc. (NYSE: MRK) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor
Czech National Bank Raises Stock Position in Merck & Co., Inc. $MRK
05:14am, Thursday, 26'th Mar 2026
Czech National Bank raised its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 3.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and E
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of T
Nasdaq, Dow Jones finish session ahead, oil price softens as US pushes for Iran peace talks
12:15pm, Wednesday, 25'th Mar 2026
4:15pm: In the green US stocks finished Wednesday’s session higher on hopes peace talks will soon resolve the US-Iran conflict. The Nasdaq was up 0.8% at...
Merck & Co., Inc. (MRK) M&A Call Transcript
11:45am, Wednesday, 25'th Mar 2026
Merck & Co., Inc. (MRK) M&A Call Transcript
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
11:20am, Wednesday, 25'th Mar 2026
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck to acquire Terns Pharmaceuticals for $6.7B
10:45am, Wednesday, 25'th Mar 2026
Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately $6.
Why Merck Might Have A Fight On Its Hands With Its $6.7 Billion Takeover Of Terns
09:04am, Wednesday, 25'th Mar 2026
Merck made plans Wednesday to beef up its cancer treatment portfolio with the $6.7 billion acquisition of Terns Pharmaceuticals.
Merck makes a big move into new cancer treatments with a $6.7 billion buyout deal
07:35am, Wednesday, 25'th Mar 2026
Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia.
Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline
07:14am, Wednesday, 25'th Mar 2026
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma
06:51am, Wednesday, 25'th Mar 2026
Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the �
